Form 4: Director William Ericson Receives PACB Stock Options

Pacific Biosciences of California director William W. Ericson was granted 223,492 stock options as part of his compensation.

Summary

• Director William W. Ericson was granted 223,492 stock options to purchase common stock in Pacific Biosciences of California, Inc.
• The options have an exercise price of $1.58 per share.
• The grant date for these options is June 3, 2026, with an expiration date of June 3, 2036.
• The options vest monthly over a one-year period, contingent upon continued service as a director.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon the director's continued service to the company.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants for board members are standard practice in the biotechnology sector to ensure alignment with long-term corporate performance and retention of key governance personnel.

Comparison to Industry Standards

• The use of monthly vesting over one year for director equity is consistent with standard corporate governance practices for mid-cap biotechnology firms.
• The grant size is typical for non-employee director compensation packages in the life sciences industry.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on a monthly basis starting July 3, 2026.

Key Dates

Keywords

PACB, Pacific Biosciences, Director Compensation, Stock Options, Insider Transaction, Form 4